Literature DB >> 30089581

Comparison of 7th and 8th editions of the UICC/AJCC TNM staging for non-small cell lung cancer in a non-metastatic North American cohort undergoing primary radiation treatment.

Rashmi Koul1, Shrinivas Rathod2, Arbind Dubey1, Bashir Bashir1, Amitava Chowdhury1.   

Abstract

BACKGROUND: We compared the performance of 7th and 8th edition of the Union for International Cancer Control (UICC) / American Joint Committee on Cancer (AJCC) TNM staging for non-small cell lung cancer (NSCLC) in non-metastatic (stage I-III) North American cohort undergoing primary radiation treatment.
METHODS: Newly diagnosed NSCLC between (Jan 2011 - Dec 2014) were screened through a Canadian Provincial Cancer Registry. Clinico-radiologically and pathologically confirmed non-metastatic NSCLC undergoing primary radiation treatment were included. Kaplan-Meier methods, Cox proportional hazard regression and Akaike information criterion (AIC) were applied to evaluate discriminatory ability and prognostic performance of 7th and 8th edition of staging systems.
RESULTS: In this cohort of 295 patients, 8th edition stages IA3, IB, IIA, IIB, IIIA, IIIB, and IIIC showed progressive increase in the hazard ratio compared to best stage IA2 (8th edition IA3 vs IA2: HR 1.72; IB vs IA2: HR 2.04; IIA vs IA2: HR 2.66; IIB vs IA2: HR 2.91; IIIA vs IA2: HR 3.38; IIIB vs IA2: HR 3.62 and IIIC vs IA2: HR 8.22). In a multivariate model, 8th edition stage grouping had smaller AIC of 2342.08 compared to 7th edition 2349.55, confirming better performance. International Association for the Study of Lung Cancer (IASLC) map based nodal categorization N1, N2 and N3, showed good survival and hazard discrimination over stage N0 (1.39, 1.48 and 2.16 respectively).
CONCLUSION: In an independent cohort of non-metastatic NSCLC undergoing primary radiation treatment, improved performance of 8th edition UICC/AJCC staging system over 7th edition was observed.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Nonsmall cell lung cancer; Radiation treatment; Staging

Mesh:

Year:  2018        PMID: 30089581     DOI: 10.1016/j.lungcan.2018.06.029

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  17 in total

1.  TNM in non-small cell lung cancer: a staging system for all oncologists or just for surgeons?

Authors:  David Ball
Journal:  Ann Transl Med       Date:  2019-07

2.  Comment on an external validation of the 8th edition of the TNM classification for lung cancer staging in patients treated with chemoradiation.

Authors:  Ramón Palmero; Arturo Navarro-Martin; Ernest Nadal
Journal:  Ann Transl Med       Date:  2019-07

3.  The 8th UICC/AJCC TNM edition for non-small cell lung cancer staging: getting off to a flying start?

Authors:  Andrea Lancia; Elisa Merizzoli; Andrea Riccardo Filippi
Journal:  Ann Transl Med       Date:  2019-09

4.  Diagnostic and prognostic value of CT perfusion parameters in patients with advanced NSCLC after chemotherapy.

Authors:  Guangyao Lin; Yuan Sui; Yiming Li; Wenqi Huang
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

5.  Functional Status and Survival in Older Nursing Home Residents With Advanced Non-Small-Cell Lung Cancer: A SEER-Medicare Analysis.

Authors:  Michael A Liu; Tamra Keeney; Alexa Papaila; Jessica Ogarek; Humera Khurshid; Elizabeth Wulff-Burchfield; Adam Olszewski; Emmanuelle Bélanger; Orestis A Panagiotou
Journal:  JCO Oncol Pract       Date:  2022-02-07

6.  LINC00501 Inhibits the Growth and Metastasis of Lung Cancer by Mediating miR-129-5p/HMGB1.

Authors:  Ruo-Tian Wang; Yi Zhang; Shu-Yang Yao; Xiao-Gang Tan
Journal:  Onco Targets Ther       Date:  2020-07-24       Impact factor: 4.147

Review 7.  Neoadjuvant apatinib plus S-1 in locally advanced pulmonary adenocarcinoma: A case report and review of the literature.

Authors:  Chu Zhang; Xiang Wang; Miao Zhang; Dong Liu; Dun-Peng Yang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

8.  SOSTDC1 inhibits bone metastasis in non-small cell lung cancer and may serve as a clinical therapeutic target.

Authors:  Guanghui Chen; Haiyi Gong; Ting Wang; Jian Wang; Zhitao Han; Guangjian Bai; Shuai Han; Xinghai Yang; Wang Zhou; Tielong Liu; Jianru Xiao
Journal:  Int J Mol Med       Date:  2018-10-10       Impact factor: 4.101

9.  A Recurrence-Specific Gene-Based Prognosis Prediction Model for Lung Adenocarcinoma through Machine Learning Algorithm.

Authors:  Shaohua Xu; Jie Zhou; Kai Liu; Zhoumiao Chen; Zhengfu He
Journal:  Biomed Res Int       Date:  2020-11-07       Impact factor: 3.411

10.  Decision-making factors for best supportive care alone and prognostic factors after best supportive care in non-small cell lung cancer patients.

Authors:  Haruna Kitazawa; Yuichiro Takeda; Go Naka; Haruhito Sugiyama
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.